Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 14/20 | 0.56 |
| ▸ | MDM2 | Q00987 | 14/20 | 0.56 |
| ▸ | GRM6 | O15303 | 6/20 | 0.54 |
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6613252 | 0.89 | TP53 (0.53) | TP53MDM2GRM6GRM5ALDH1A1 | |
| SCHEMBL1929543 | 0.84 | GRM6 (0.70) | TP53MDM2GRM6GRM5ALDH1A1 | |
| SCHEMBL4099130 | 0.84 | GRM6 (0.74) | GRM6GRM5ALDH1A1GAAMAPT | |
| SCHEMBL6157860 | 0.84 | TP53 (0.75) | TP53MDM2GRM6GRM5ALDH1A1 | |
| SCHEMBL10489596 | 0.83 | GRM6 (0.76) | TP53MDM2GRM6GRM5ALDH1A1 | |
| SCHEMBL25758961 | 0.81 | GRM6 (0.76) | TP53MDM2GRM6GRM5ALDH1A1 | |
| SCHEMBL1383438 | 0.81 | ALDH1A1 (0.47) | TP53MDM2ALDH1A1GAAMAPT | |
| SCHEMBL27503307 | 0.76 | GAA (0.50) | TP53MDM2GRM6ALDH1A1GAA | |
| SCHEMBL27461391 | 0.74 | GRM6 (0.60) | TP53MDM2GRM6GRM5ALDH1A1 | |
| SCHEMBL5212225 | 0.74 | RIPK2 (0.46) | TP53GRM6GRM5ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181962-A1 | Substituted thiophene compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2009-07-16 | — | — | US | disclosed |
| US-7358376-B2 | Substituted Thiophene compounds | ASTRAZENECA AB (SE) | 2008-04-15 | — | — | US | disclosed |
| CN-1243747-C | Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme IKK-2 | ASTRAZENECA AB (SE) | 2006-03-01 | — | — | CN | disclosed |
| EP-1261600-B1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 | ASTRAZENECA AB (SE) | 2004-05-06 | — | — | EP | disclosed |
| CN-1425012-A | Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme IKK-2 | ASTRAZENECA AB (SE) | 2003-06-18 | — | — | CN | disclosed |
| EP-1261600-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 | AstraZeneca AB (SE) | 2002-12-04 | — | — | EP | disclosed |
| US-20020107252-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2002-08-08 | — | — | US | disclosed |
| WO-2001058890-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 | ASTRAZENECA AB (SE) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181962-A1 | Substituted thiophene compounds | ABCG2, SULT1E1, TPMT | TP53 1639/4885MDM2 2183/4885GRM6 2715/4885 |
| US-20020107252-A1 | Novel Compounds | UGT1A1, CYP1B1, CYP1A1 | TP53 2971/4885MDM2 3275/4885GRM6 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.